<DOC>
	<DOCNO>NCT01380314</DOCNO>
	<brief_summary>Cutaneous leishmaniasis endemic New World approximately US-Mexican border Central America Northern part South America level Rio de Janeiro . Until recently , standard treatment leishmaniases pentavalent antimony ( Glucantime Pentostam ) . The cure rate L panamensis Colombia 91 % -93 % [ Soto , 1993 ; Velez , 1997 ] , large study several formulation antimony find combined Bolivia-Colombia cure rate 86 % [ Soto , 2004b ] , work complete , cure rate Palos Blancos , Bolivia 15 16 = 94 % [ Soto , manuscript preparation ] . Nevertheless , pentavalent antimonials disadvantage multiple injection mild-moderate clinical toxicity [ gastrointestinal complaint , liver enzyme elevation , pancreatic enzyme elevation ] , particularly unpleasant moderate clinical problem cutaneous leishmaniasis . The oral agent Miltefosine show effective antimony Colombia Bolivia . In Colombia , cure rate miltefosine 91 % [ Soto 2004a ] just-completed trial Palos Blancos , cure rate miltefosine 32 37 = 88 % . Side effect see patient cutaneous disease specifically attribute drug nausea vomit mild grade approximately 25 % patient , low-grade elevation creatinine also approximately 25 % patient [ Soto 2001 ; Soto 2004 ] . The 6-month cure rate reach 100 % , miltefosine relatively slow cure compare Sb . 31 44 evaluable miltefosine patient ( 70 % ) cure 1 month therapy , compare 16 16 evaluable Glucantime patient ( 100 % ) . Imiquimod ( Aldara ; 3M Pharmaceuticals ) novel immune response-activating compound , approve FDA cervical wart , activate macrophage kill Leishmania specie . Combined imiquimod plus Glucantime use rescue treatment 12 patient Peruvian cutaneous leishmaniasis previously respond Glucantime alone . 90 % patient cure 6-month follow-up period [ Arevalo , 2001 ] . In follow study [ Miranda-Verastegui et al , 2005 ] , na√Øve patient randomize combination Sb plus imiquimod ( 18 patient ) vs Sb plus placebo ( 20 patient ) . The cure rate 1 month therapy 50 % imiquimod +Sb group compare 15 % placebo+Sb group ( p = 0.02 ) . By 12 month therapy , Sb+placebo group catch , cure rate 72 % -75 % group . Local side effect evaluate . Edema , itching , burning , pain equal two group . There erythema imiquimod grup ( 55 % patient ) compare placebo group ( 25 % patient ) . The Imiquimod study neighbor Peru suggest combination immunomodulator capable decreasing time cure , potentially increase cure rate , Andean cutaneous leishmaniasis . The present study evaluate combination oral miltefosine plus topical imiquimod cutaneous leishmaniasis Bolivia . If first group patient , cure rate 1 month therapy appreciably 70 % historic value miltefosine alone cure rate 6 month great 88 % historic value miltefosine alone , subsequent patient randomize miltefosine+imiquimod miltefosine+placebo cream .</brief_summary>
	<brief_title>Oral Miltefosine Plus Topical Imiquimod Treat Cutaneous Leishmaniasis</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Gender : Male female Age : &gt; 12 yr age Presentation : At least 1 lesion must ulcerative . No 3 lesion . Parasitology : Parasitological confirmation 1 lesion make visualization culture leishmania biopsy aspirate lesion . No specific putatively specific therapy ( Sb , pentamidine , amphotericin B , imidazole , allopurinol ) last 6 month Previous treatment leishmaniasis concomitant diseases history abnormal complete blood count ( white blood count , hemoglobin , platelet count ) , value liver transaminase ( SGOT ) , kidney function test ( creatinine ) . pregnancy breastfeed willing take contraception 3 month end treatment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>leishmaniasis</keyword>
	<keyword>cutaneois leishmaniasis</keyword>
	<keyword>miltefosine</keyword>
	<keyword>oral therapy</keyword>
	<keyword>treatment</keyword>
	<keyword>imiquimod</keyword>
</DOC>